C-Type Natriuretic Peptide (CNP) (1-22), human TFA

发表于由

C-Type Natriuretic Peptide (CNP) (1-22), human TFA; 纯度: 99.78%

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)，是 CNP 的 1-22 片段，是一种利钠肽受体 B (NPR-B) 激动剂。C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) 抑制由生理激动剂组胺和 5-HT 刺激或直接由 Forskolin 刺激的 cAMP 合成。CNP 是一种有效的、内皮衍生的松弛剂和生长抑制因子。

C-Type Natriuretic Peptide (CNP) (1-22), human TFAamp;;

C-Type Natriuretic Peptide (CNP) (1-22), human TFA Chemical Structure

CAS No. : 1966153-17-2

规格 价格 是否有货 数量
500 μg ￥1400 In-stock
1 mg ￥2200 In-stock
5 mg ￥8800 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].

IC50 Target[1]

NPR-B

;

体外研究
(In Vitro)

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1].
PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]:

Dose
(nM/kg)		 AUC0→∞
(pM・min/mL)		 MRT0→∞
(min)		 T1/2
(min)		 CLtot
(mL/min/kg)		 Vdss
(mL/kg)
20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]:

Dose
(nM/kg)		 Cmax
(pM/mL)		 Tmax
(min)		 AUC0→∞
(pM・min/mL)		 MRT0→∞
(min)		 T1/2
(min)		 BA
(%)
50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9

Each value represents the mean±SD of 3 rats. MRT=mean residence time, CLtot=total clearance, T1/2=half-life period, BA=bioavailability.
i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2311.62

Formula

C95H158F3N27O30S3
CAS 号

1966153-17-2
Sequence Shortening

GLSKGCFGLKLDRIGSMSGLGC (Disulfide bridge: Cys6-Cys22)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 2 mg/mL (0.87 mM; Need ultrasonic)
参考文献

  • [1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680.

    [2]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.